Aclaris Therapeutics (NASDAQ: ACRS) has recently received a number of price target changes and ratings updates:

  • 8/9/2017 – Aclaris Therapeutics was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/9/2017 – Aclaris Therapeutics was given a new $50.00 price target on by analysts at Cantor Fitzgerald. They now have a “buy” rating on the stock.
  • 8/2/2017 – Aclaris Therapeutics was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 7/31/2017 – Aclaris Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $36.00 price target on the stock.
  • 7/24/2017 – Aclaris Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 7/4/2017 – Aclaris Therapeutics had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $40.00 price target on the stock.
  • 6/28/2017 – Aclaris Therapeutics had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $36.00 price target on the stock.
  • 6/16/2017 – Aclaris Therapeutics is now covered by analysts at Cantor Fitzgerald. They set an “overweight” rating and a $50.00 price target on the stock.
  • 6/15/2017 – Aclaris Therapeutics was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

Aclaris Therapeutics, Inc. (ACRS) traded up 6.02% during mid-day trading on Monday, hitting $26.59. The company had a trading volume of 337,826 shares. The company has a 50-day moving average price of $27.77 and a 200 day moving average price of $27.95. Aclaris Therapeutics, Inc. has a 12 month low of $18.74 and a 12 month high of $33.25. The firm’s market capitalization is $710.91 million.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.68) by $0.12. Equities analysts forecast that Aclaris Therapeutics, Inc. will post ($3.10) EPS for the current fiscal year.

Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.

Receive News & Ratings for Aclaris Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.